The Effect of the Mediterranean Diet on Metabolic Health: A Systematic Review and Meta-Analysis of Controlled Trials in Adults.
Study Goal
The researchers aimed to examine the Mediterranean diet's effect on metabolic syndrome incidence, components, risk factors, and related comorbidities, not specifically Alanine.
Results Summary
The abstract does not mention Alanine or its effects; it focuses on the Mediterranean diet's impact on metabolic health outcomes.
Population
Adults in controlled trials comparing the Mediterranean diet with no treatment, usual care, or different diets.
Effective Dosage
Not mentioned
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Mediterranean diet (MD) | increase | metabolic health | adults | - | may provide metabolic benefits | #1 |
Mediterranean diet (MD) | neutral | metabolic syndrome (MetSyn) incidence | adults | - | examined the MD's effect | #2 |
Mediterranean diet (MD) | neutral | MetSyn components | adults | - | examined the MD's effect | #3 |
Mediterranean diet (MD) | neutral | MetSyn risk factors | adults | - | examined the MD's effect | #4 |
Mediterranean diet (MD) | neutral | incidence from MetSyn-related comorbidities | adults | - | examined the MD's effect | #5 |
Mediterranean diet (MD) | neutral | mortality from MetSyn-related comorbidities | adults | - | examined the MD's effect | #6 |
Mediterranean diet (MD) | neutral | receipt of pharmacologic treatment for MetSyn components | adults | - | examined the MD's effect | #7 |
Mediterranean diet (MD) | neutral | receipt of pharmacologic treatment for MetSyn comorbidities | adults | - | examined the MD's effect | #8 |
The Mediterranean diet (MD) may provide metabolic benefits but no systematic review to date has examined its effect on a multitude of outcomes related to metabolic health. This systematic review with meta-analysis (International Prospective Register of Systematic Reviews, PROSPERO; number CRD42019141459) aimed to examine the MD's effect on metabolic syndrome (MetSyn) incidence, components and risk factors (primary outcomes), and incidence and/or mortality from MetSyn-related comorbidities and receipt of pharmacologic treatment for MetSyn components and comorbidities (secondary outcomes). We searched Pubmed, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Web of Science for controlled trials published until June 2019, comparing the MD with no treatment, usual care, or different diets in adults. Studies not published in English and not promoting the whole MD were excluded. Two authors independently extracted data and assessed risk of bias using the Cochrane Collaboration's and Risk of Bias in non-randomised studies (ROBINS-I) tools. Reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Random-effects meta-analyses, subgroup analyses and meta-regressions were performed, and heterogeneity was quantified using the I